Objective To explore the clinical efficacy and safety of Nintedanib in the treatment of progressive pulmonary fibros-ing.Methods Clinical data of 80 patients diagnosed with PPF who were hospitalized in the First Affiliated Hospital of Jinzhou Medi-cal University from June 2022 to October 2023 were retrospectively analyzed.According to whether Nidanib was used,37 cases were divided into the conventional treatment group and 43 cases were divided into the Nidanib treatment group.The cause of the disease was determined through perfect examination,and the etiological treatment and symptomatic treatment were given.The Nidanib treatment group was given combined Nidanib treatment on this basis.Lung function DLCO％,FVC％index,PaO2,6MWT distance,chest HRCT score and incidence of adverse reactions were compared between the two groups before treatment and 6 months after treatment.Results FVC％,DLCO％,PaO2 and 6MWT distance in Nidanib treatment group were better than those in conventional treatment group(P<0.05).The decrease rates of FVC％and DLCO％in Nidanib group were lower than those in conventional treatment group(P<0.05).In terms of chest HRCT score,the score of Nidanib treatment group after treatment was lower than that of conventional treatment group,and the difference was statistically significant(P<0.05),indicating that Nidanib could help delay the progression of PPF.In terms of safety evaluation,after 6 months of treatment and observation,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Combined treatment with Nintedanib can delay the decline of pul-monary function in PPF patients,delay the progression of pulmonary fibrosis,improve quality of life and do not increase the incidence of adverse reactions during the treatment period
progressive pulmonary fibrosingNintedanibpulmonary function test6 minutes walking test
NETL
NSTL
万方数据
